Robert Langreth - The Japan Times

WORLD / Science & Health

Jul 7, 2023

Eisai Alzheimer’s drug gets full U.S. approval, widening access to the therapy

The broader clearance from the Food and Drug Administration marks a milestone for treatment of the dementia that afflicts some 6 million Americans.

BUSINESS

Jun 1, 2023

Obesity and Alzheimer’s news makes Eli Lilly world’s most valuable drugmaker

An 8.5% gain in May for Eli Lilly lifted its shares to a record high, while displaced Johnson & Johnson slumped 5.3% during the month.

BUSINESS

Nov 30, 2022

Eisai Alzheimer’s drug sparks debate over benefits as risks like brain bleeding emerge

The key issue is whether the modest slowing of the disease is meaningful to individual patients and their families, especially in light of the potential side effects.

WORLD / Science & Health

Nov 23, 2022

Bivalent COVID boosters give some protection in CDC study, but not much

Experts say it’s still unclear whether the updated shots are any better than earlier versions at preventing hospitalization and severe illness.

JAPAN / Science & Health

Sep 28, 2022

Alzheimer’s progression slowed by drug in major trial

The drug slowed cognitive decline in people with early Alzheimer’s by 27% over 18 months when compared with a placebo using a common rating scale.

BUSINESS / Companies

Jul 6, 2022

Eisai says Alzheimer’s drug will get priority review in U.S.

Under the accelerated approval pathway, drugs can be approved based on their ability to remove amyloid, a hallmark of the disease, from the brain.

BUSINESS

Mar 15, 2022

Drugmakers pause trials in Russia while still sending medicine

Major pharmaceutical firms are seeking to strike a balance between international opprobrium over Russia’s invasion of Ukraine and the needs of sick patients.

WORLD / Science & Health

Jan 12, 2022

Biogen stung as U.S. limits coverage of Alzheimer’s therapy

Private insurers in the U.S. have mostly declined to cover Aduhelm, saying they need more proof of its efficacy and that benefits outweigh risks like brain swelling.

WORLD / Science & Health

Nov 5, 2021

Pfizer develops COVID-19 pill that cuts hospitalizations and deaths by 89%

The drugmaker claims ‘overwhelming efficacy” and plans to submit their findings for emergency authorization as soon as possible.

WORLD

Oct 30, 2021

Pfizer won the first round, but Moderna sees final victory ahead

Pfizer has been first across the finish line in nearly every leg of the COVID-19 vaccine race, but Moderna executives say their company’s mRNA technology gives it an advantage.

WORLD / Science & Health

Sep 5, 2021

The Moderna vaccine makes more antibodies than Pfizer’s. Does it matter?

Subtle differences between the Pfizer Inc.-BioNTech SE and Moderna Inc. vaccines are emerging across patient groups over time, but what this all means in the real world is still unclear.

WORLD

Sep 3, 2021

Lawmakers probe ‘anomalies’ in approval of Biogen Alzheimer’s drug

The congressional inquiry adds to pressure on the U.S. agency charged with regulating products that account for one-fifth of consumer spending.

WORLD / Science & Health

Sep 1, 2021

Moderna’s shot makes twice as many antibodies as Pfizer’s, study says

Moderna’s COVID-19 vaccine generated more than double the antibodies of a similar shot made by Pfizer and BioNTech in research that compared immune responses evoked by the two inoculations.

WORLD / Science & Health

Jul 29, 2021

Doctors blast Biogen Alzheimer approval as ‘regulatory failure’

The New England Journal of Medicine opinion piece is another sign of persistent furor over the agency’s decision.

WORLD

Jul 28, 2021

A pandemic-weary world is facing a distressing reality check

Around the globe, people and governments are finding out that COVID-19 won’t be thrashed into extinction, but is more likely to enter a long, endemic tail.

WORLD

Jun 15, 2021

Novavax COVID-19 shot highly effective against variants in trial

The company plans to apply for regulatory clearance globally, with much of the first available doses going to low- and middle-income countries.

JAPAN / Science & Health

Jun 8, 2021

Changing the game for Alzheimer’s treatment, U.S. approves Eisai and Biogen’s drug

The approval appears to signal a fundamental shift in the way the FDA thinks about Alzheimer’s disease, which could have lasting ramifications for other drugs in the pipeline.

WORLD / Science & Health

Apr 14, 2021

Vaccine blood-clot side effect puts focus on immune reaction

Health officials are exploring whether and how an immune reaction may occur in people who have received vaccines made by AstraZeneca and Johnson & Johnson.

WORLD

Jan 31, 2021

COVID-19 mutations undercut optimism even as more vaccines near

Mutations that likely confer partial resistance to vaccines and antibody treatments are now prevalent in both South Africa and Brazil, and they are threatening to spread worldwide.

WORLD / Science & Health

Dec 4, 2020

Pfizer scaled back COVID-19 vaccine output targets earlier this year

Pfizer Inc. scaled back its COVID-19 production targets earlier this year after the drugmaker ran into difficulties securing all the materials it needs to produce the shots at a large scale.

91仓库

author

Meta

Podcast

Longform

SUSTAINABLE JAPAN

SPECIAL SUPPLEMENTS

SUPPLEMENTS BINDER

In your social network

In your inbox

In your social network

In your inbox